-- 
Kamada Rises Most Since March on Patent for Alpha 1 Antitrypsin

-- B y   R o n i t   G o o d m a n
-- 
2011-04-10T10:14:41Z

-- http://www.bloomberg.com/news/2011-04-10/kamada-rises-most-since-march-on-patent-for-alpha-1-antitrypsin.html
Kamada Ltd. (KMDA)  climbed the most this
month after the biopharmaceutical company said it received a
U.S. patent for the use of its alpha 1 antitrypsin to treat
exacerbation episodes of pulmonary diseases.  The shares advanced 3.4 percent, the biggest gain since
March 30, to 31.30 shekels at 1:04 p.m. in  Tel Aviv , giving the
Nes Ziona, Israel-based company a market value of 862 million
shekels ($251 million).  To contact the reporter on this story:
Ronit Goodman in Tel Aviv at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  